JP2001510479A5 - - Google Patents

Download PDF

Info

Publication number
JP2001510479A5
JP2001510479A5 JP1998533785A JP53378598A JP2001510479A5 JP 2001510479 A5 JP2001510479 A5 JP 2001510479A5 JP 1998533785 A JP1998533785 A JP 1998533785A JP 53378598 A JP53378598 A JP 53378598A JP 2001510479 A5 JP2001510479 A5 JP 2001510479A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998533785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510479A (ja
JP4324249B2 (ja
Filing date
Publication date
Priority claimed from DE19706061A external-priority patent/DE19706061A1/de
Application filed filed Critical
Publication of JP2001510479A publication Critical patent/JP2001510479A/ja
Publication of JP2001510479A5 publication Critical patent/JP2001510479A5/ja
Application granted granted Critical
Publication of JP4324249B2 publication Critical patent/JP4324249B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP53378598A 1997-02-07 1998-02-09 フッ素化１７α−アルキル鎖を有する抗ゲスタゲン作用性ステロイド Expired - Fee Related JP4324249B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19706061.7 1997-02-07
DE19706061A DE19706061A1 (de) 1997-02-07 1997-02-07 Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PCT/EP1998/000752 WO1998034947A1 (de) 1997-02-07 1998-02-09 ANTIGESTAGEN WIRKSAME STEROIDE MIT FLUORIERTER 17α-ALKYLKETTE

Publications (3)

Publication Number Publication Date
JP2001510479A JP2001510479A (ja) 2001-07-31
JP2001510479A5 true JP2001510479A5 (https=) 2005-07-14
JP4324249B2 JP4324249B2 (ja) 2009-09-02

Family

ID=7820508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53378598A Expired - Fee Related JP4324249B2 (ja) 1997-02-07 1998-02-09 フッ素化１７α−アルキル鎖を有する抗ゲスタゲン作用性ステロイド

Country Status (35)

Country Link
US (4) US6316432B1 (https=)
EP (1) EP0970103B1 (https=)
JP (1) JP4324249B2 (https=)
KR (1) KR100511815B1 (https=)
CN (2) CN1246865A (https=)
AR (1) AR010887A1 (https=)
AT (1) ATE216397T1 (https=)
AU (1) AU742834B2 (https=)
BG (1) BG63875B1 (https=)
BR (1) BR9807667A (https=)
CA (1) CA2280041C (https=)
CL (1) CL2004001191A1 (https=)
CZ (1) CZ296328B6 (https=)
DE (2) DE19706061A1 (https=)
DK (1) DK0970103T3 (https=)
EA (1) EA003092B1 (https=)
EE (1) EE03831B1 (https=)
ES (1) ES2175673T3 (https=)
HK (1) HK1040718B (https=)
HU (1) HUP0000968A3 (https=)
ID (1) ID22643A (https=)
IL (1) IL131226A (https=)
IS (1) IS2190B (https=)
MY (1) MY118508A (https=)
NO (1) NO313554B1 (https=)
NZ (1) NZ336989A (https=)
PL (1) PL191808B1 (https=)
PT (1) PT970103E (https=)
SI (1) SI0970103T1 (https=)
SK (1) SK283155B6 (https=)
TR (1) TR199901855T2 (https=)
TW (1) TW499434B (https=)
UA (1) UA66783C2 (https=)
WO (1) WO1998034947A1 (https=)
ZA (1) ZA98985B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
UY26966A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
EP1326617B9 (en) * 2000-10-18 2006-10-25 Schering Aktiengesellschaft Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
DE10051609A1 (de) * 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
UY26965A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
EP1328276B1 (en) 2000-10-18 2005-11-23 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
AU2002215958B2 (en) * 2000-10-18 2006-08-17 Schering Ag Use of inhibitors of progesterone receptor for treating cancer
PL361689A1 (en) * 2001-01-09 2004-10-04 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE307823T1 (de) * 2002-05-03 2005-11-15 Schering Ag 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
US7593347B2 (en) * 2003-12-29 2009-09-22 Intel Corporation Method and apparatus to exchange channel information
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
HUE036870T2 (hu) 2006-10-24 2018-08-28 Repros Therapeutics Inc Az endometriális proliferáció elnyomására szolgáló készítmények és módszerek
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP3865502A1 (en) 2010-03-22 2021-08-18 Allergan Pharmaceuticals International Limited Compositions and methods for non-toxic delivery of cdb-2914
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
TN2015000454A1 (en) 2013-04-11 2017-04-06 Bayer Pharma AG Progesterone receptor antagonist dosage form
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868321A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for inhibiting autocrine HCG production in adult human cells
TN2017000482A1 (en) 2015-05-18 2019-04-12 Bayer Pharma AG Selective progesterone receptor modulator (sprm) regimen.
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE310541C (https=) * 1915-12-19 1919-01-30
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
EP0369881A1 (fr) * 1988-11-16 1990-05-23 Roussel-Uclaf Nouveaux produits dérivés de la structure 3-céto delta-4,9 19-nor stéroides et leur application comme médicaments
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Similar Documents

Publication Publication Date Title
JP2000507042A5 (https=)
JP2001514772A5 (https=)
JP2000510751A5 (https=)
JP2000509635A5 (https=)
JP2000509637A5 (https=)
JP2000509942A5 (https=)
JP2000509912A5 (https=)
JP2002513308A5 (https=)
JP2002511917A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2001522452A5 (https=)
JP2001519714A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2001510479A5 (https=)
JP2000508841A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000508836A5 (https=)
JP2000508102A5 (https=)